Mycophenolate mofetil for non‐renal manifestations of systemic lupus erythematosus: a systematic review

References

• Mok C. C., Lai K. N. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002; 40: 447–57
   PubMed Web of Science ®Google Scholar
• Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–28
   PubMed Web of Science ®Google Scholar
• Chan T. M., Li F. K., Tang C. S., Wong R. W., Fang G. X., Ji Y. L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong–Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156–62
   PubMed Web of Science ®Google Scholar
• Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–80
   PubMed Web of Science ®Google Scholar
• Dooley M. A., Cosio F. G., Nachman P. H., Falkenhain M. E., Hogan S. L., Falk R. J., et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833–9
   PubMed Web of Science ®Google Scholar
• Spetie D. N., Tang Y., Rovin B. H., Nadasdy T., Nadasdy G., Pesavento T. E., et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66: 2411–15
   PubMed Web of Science ®Google Scholar
• Gaubitz M., Schorat A., Schotte H., Kern P., Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731–6
   PubMed Web of Science ®Google Scholar
• Alba P., Karim M. Y., Hunt B. J. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633–5
   PubMed Web of Science ®Google Scholar
• Vasoo S., Thumboo J., Fong K. Y. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12: 630–2
   PubMed Web of Science ®Google Scholar
• Mak A., Mok C. C. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14: 856–8
   PubMed Web of Science ®Google Scholar
• Arcasoy M. O., Chao N. J. T‐cell‐mediated pure red‐cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol 2005; 78: 161–3
   PubMedGoogle Scholar
• Pisoni C. N., Sanchez F. J., Karim Y., Cuadrado M. J., D'Cruz D. P., Abbs I. C., et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047–52
   PubMed Web of Science ®Google Scholar
• Goyal S., Nousari H. C. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142–4
   PubMed Web of Science ®Google Scholar
• Boehm I., Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235–6
   PubMedGoogle Scholar
• Schanz S., Ulmer A., Rassner G., Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174–8
   PubMed Web of Science ®Google Scholar
• Hanjani N. M., Nousari C. H. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138: 1616–18
   PubMedGoogle Scholar
• Pisoni C. N., Obermoser G., Cuadrado M. J., Sanchez F. J., Karim Y., Sepp N. T., et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23: 393–6
   PubMed Web of Science ®Google Scholar
• Lhotta K., Wurzner R., Rosenkranz A. R., Beer R., Rudisch A., Neumair F., et al. Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 2004; 13: 139–41
   PubMedGoogle Scholar
• Jose J., Paulose B. K., Vasuki Z., Danda D. Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci 2005; 59: 353–6
   PubMedGoogle Scholar
• Mok C. C., Mak A., To C. H. Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis 2006; 65: 971–3
   PubMed Web of Science ®Google Scholar
• Riskalla M. M., Somers E. C., Fatica R. A., McCune W. J. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508–12
   PubMed Web of Science ®Google Scholar
• Karim M. Y., Alba P., Cuadrado M. J., Abbs I. C., D'Cruz D. P., Khamashta M. A., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876–82
   PubMed Web of Science ®Google Scholar
• Perrin L., Giurgea I., Baudet‐Bonneville V., Deschenes G., Bensman A., Ulinski T. Acute pancreatitis in paediatric systemic lupus erythematosus. Acta Paediatr 2006; 95: 121–4
   PubMedGoogle Scholar
• Gehi A., Webb A., Nolte M., Davis J Jr. Treatment of systemic lupus erythematosus‐associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum 2003; 48: 1067–70
   PubMed Web of Science ®Google Scholar
• Caponnetto C., Rossi E., Primavera A. Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection. Eur Neurol 2001; 46: 53–4
   PubMedGoogle Scholar
• Bijl M., Horst G., Bootsma H., Limburg P. C., Kallenberg C. G. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534–9
   PubMed Web of Science ®Google Scholar
• Bootsma H., Spronk P., Derksen R., de Boer G., Wolters‐Dicke H., Hermans J., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595–9
   PubMedGoogle Scholar
• Ong L. M., Hooi L. S., Lim T. O., Goh B. L., Ahmad G., Ghazalli R., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504–10
   PubMed Web of Science ®Google Scholar
• Allison A. C., Eugiu E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118
   PubMed Web of Science ®Google Scholar
• Takahashi K., Reynolds M., Ogawa N., Longo D. L., Burdick J. Augmentation of T‐cell apoptosis by immunosuppressive agents. Clin Transplant 2004; 18((Suppl 12))72–5
   PubMedGoogle Scholar
• Cohn R. G., Mirkovich A., Dunlap B., Burton P., Chiu S. H., Eugui E., et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411–18
   PubMed Web of Science ®Google Scholar
• Nakamura M., Ogawa N., Shalabi A., Maley W. R., Longo D., Burdick J. F. Positive effect on T‐cell regulatory apoptosis by mycophenolate mofetil. Clin Transplant 2001; 15((Suppl 6))36–40
   PubMedGoogle Scholar
• Hauser I. A., Johnson D. R., Thevenod F., Goppelt‐Strube M. Effect of mycophenolic acid on TNF alpha‐induced expression of cell adhesion molecules in human venous endothelial cells in vitro. Br J Pharmacol 1997; 122: 1315–22
   PubMedGoogle Scholar
• Glomsda B. A., Blaheta R. A., Hailer N. P. Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord 2003; 41: 610–19
   PubMed Web of Science ®Google Scholar
• Fossati‐Jimack L., Ioan‐Facsinay A., Reininger L., Chicheportiche Y., Watanabe N., Saito T., et al. Markedly different pathogenicity of four immunoglobulin G isotype‐switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low‐affinity Fcgamma receptor III. J Exp Med 2000; 191: 1293–302
   PubMed Web of Science ®Google Scholar
• Jonsson C. A., Carlsten H. Mycophenolic acid inhibits inosine 5′‐monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003; 3: 31–7
   PubMed Web of Science ®Google Scholar
• Ramos M. A., Pinera C., Setien M. A., Buelta L., de Cos M. A., de Francisco A. L., et al. Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB×NZW)F1 mice. Nephrol Dial Transplant 2003; 18: 878–83
   PubMed Web of Science ®Google Scholar
• Semple J. W. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9–12
   PubMed Web of Science ®Google Scholar
• Moder K. G. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15–19
   PubMed Web of Science ®Google Scholar
• Tran G. T., Carter N., Hodgkinson S. J. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int Immunopharmacol 2001; 1: 1709–23
   PubMedGoogle Scholar
• Lui S. L., Tsang R., Wong D., Chan K. W., Chan T. M., Fung P. C., et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus‐prone MRL/lpr mice. Lupus 2002; 11: 411–18
   PubMed Web of Science ®Google Scholar
• Miljkovic D. J., Cvetkovic I., Stosic‐Grujicic S., Trajkovic V. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. Clin Exp Immunol 2003; 132: 239–46
   PubMed Web of Science ®Google Scholar
• Jonsson C. A., Carlsten H. Mycophenolic acid inhibits inosine 5′‐monophosphate dehydrogenase and suppresses production of pro‐inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol 2002; 216: 93–101
   PubMed Web of Science ®Google Scholar
• Miljkovic D., Samardzic T., Cvetkovic I., Mostarica Stojkovic M., Trajkovic V. Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes. Glia 2002; 39: 247–55
   PubMedGoogle Scholar
• Dehghani F., Hischebeth G. T., Wirjatijasa F., Kohl A., Korf H. W., Hailer N. P. The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures. Eur J Neurosci 2003; 18: 1061–72
   PubMedGoogle Scholar
• Eisenberg R. Update on rituximab. Ann Rheum Dis 2005; 64((Suppl 4))55–7
   Google Scholar